{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:59:17Z","timestamp":1758819557582},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1684\/bdc.2011.1436","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:33Z","timestamp":1565726313000},"page":"E80-E89","source":"Crossref","is-referenced-by-count":4,"title":["Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study"],"prefix":"10.1016","volume":"98","author":[{"given":"Ir\u00e8ne","family":"Asmane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Bajard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Guastalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Intidhar","family":"Labidi Galy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Moullet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ardisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Coeffic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bergerat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1684\/bdc.2011.1436_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ijgc-00009577-200505001-00002","article-title":"Treatment goals in ovarian cancer","volume":"15","author":"Ozols","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0010","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1436_bib0015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1200\/JCO.2002.20.5.1161","article-title":"Recurrent ovarian cancer: evidence-based treatment","volume":"20","author":"Ozols","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1684\/bdc.2011.1436_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ijgc-00009577-200505001-00007","article-title":"Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","article-title":"Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs","volume":"10","author":"Harter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1684\/bdc.2011.1436_bib0030","first-page":"4195","article-title":"Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial","volume":"29","author":"Weber","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1684\/bdc.2011.1436_bib0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventionnal platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parman","year":"2003","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1436_bib0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000088959","article-title":"Topotecan in platinum-resistant epithelial ovarian cancer","volume":"51","author":"Karabulut","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1684\/bdc.2011.1436_bib0060","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0065","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0070","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1436_bib0075","first-page":"1105","article-title":"Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms","volume":"74","author":"Abu-Jawdeh","year":"1996","journal-title":"Lab Invest"},{"key":"10.1684\/bdc.2011.1436_bib0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1436_bib0085","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J Mol Med"},{"key":"10.1684\/bdc.2011.1436_bib0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ygyno.2004.12.001","article-title":"Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer","volume":"96","author":"Monk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0100","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0105","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0110","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1436_bib0115","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1436_bib0120","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1436_bib0125","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0002-9440(10)64467-7","article-title":"Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer","volume":"161","author":"Hu","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1684\/bdc.2011.1436_bib0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3816\/CBC.2008.n.045","article-title":"RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer","volume":"8","author":"O'Shaughnessy","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"10 Suppl.","key":"10.1684\/bdc.2011.1436_bib0145","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1525-1438.2007.01027.x","article-title":"A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer","volume":"18","author":"Wright","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2006.01.030","article-title":"Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer","volume":"102","author":"Cohn","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0165","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","article-title":"Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer","volume":"115","author":"Hurt","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0170","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal perforation due to bevacizumab in colorectal cancer","volume":"14","author":"Saif","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0175","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/1097-0142(19890515)63:10<1944::AID-CNCR2820631013>3.0.CO;2-#","article-title":"Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest","volume":"63","author":"Hruban","year":"1989","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/gyno.1997.4842","article-title":"A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer","volume":"67","author":"Seewaldt","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","article-title":"Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1436_bib0190","first-page":"541","article-title":"Colonic perforation secondary to taxol therapy: an unusual presentation","volume":"29","author":"de Haan","year":"2006","journal-title":"Onkologie"},{"key":"10.1684\/bdc.2011.1436_bib0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.05.031","article-title":"The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study","volume":"114","author":"Sfakianos","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2011.1436_bib0200","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba1","article-title":"Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer: a Gynecologic Oncology Group study","volume":"28","author":"Burger","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:37:45Z","timestamp":1602491865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0007455115305920"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1436","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}